Irinotecan hydrochloride Injection 100 mg in 5 mL (10)

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

irinotecan hydrochloride trihydrate, Quantity: 20 mg/mL

Disponible depuis:

Pfizer (Perth) Pty Ltd

forme pharmaceutique:

Injection, concentrated

Composition:

Excipient Ingredients: sorbitol; water for injections; lactic acid

Mode d'administration:

Intravenous

Unités en paquet:

1 X 5 mL

Type d'ordonnance:

(S1) This Schedule is intentionally blank

indications thérapeutiques:

Irinotecan is indicated for single-agent or combination treatment of patients with: ? Metastatic carcinoma of the colon or rectum that has recurred or progressed following 5-fluorouracil (5-FU)-based therapy ? Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. ? Previously untreated metastatic carcinoma of the colon or rectum ? Advanced cervical squamous cell carcinoma ? Irinotecan in combination with 5-FU, folinic acid (FA) and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Descriptif du produit:

Visual Identification: Clear, light yellow solution, free from visible particles.; Container Type: Vial; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Listed (Export Only)

Date de l'autorisation:

2019-09-03